BIIB vs REPL · P/E 21, rev $9.89B vs $825.7M cap
Biogen Inc (BIIB) versus Replimune Group Inc (REPL) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
REPL does not have a complete income-statement cache yet.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. REPL currently screens at market cap $825.7M.
Not investment advice. Open the BIIB and REPL stock pages for the full models.
Not investment advice.